Henry Schein stock holds steady as 2026 outlook is raised and Q2 earnings beat
Published on 08/21/2026 at 11:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Henry Schein Inc. (US42548G1040) has strengthened its guidance for 2026 after reporting Q2 2026 results that exceeded earnings expectations, with adjusted earnings per share of $1.27 on revenue of $3.5 billion as reported on August 4, 2026. Per a recent earnings overview published on August 20, 2026, the company now expects full-year 2026 adjusted EPS between $5.29 and $5.39, signaling faster profit growth than initially planned.
Outlook raised for 2026 growth
According to a guidance update summarized on August 21, 2026, Henry Schein lifted its projected 2026 total sales growth to a range of 4.5% to 5.5%, up from a prior range of 3% to 5%. The same report notes that management now anticipates internal local-currency growth of 3.5% to 4.5% for the second half of 2026, compared with 3.6% in the first half, even against a tougher prior-year comparison. The company also forecasts adjusted EBITDA growth in the mid- to high-single digits for 2026, supporting the upgraded EPS range of $5.29 to $5.39.
The raised outlook means that, at the midpoint, Henry Schein is targeting full-year 2026 adjusted EPS of $5.34, which would represent approximately 7.7% growth compared with the prior year’s diluted EPS of $4.96 mentioned in the recent consensus commentary. That same overview highlights that analysts currently expect full-year 2026 adjusted EPS of $5.35, placing the company’s midpoint guidance fractionally above the average forecast and indicating confidence in sustaining margin expansion.
Q2 2026 earnings beat and valuation context
An earnings recap published on August 20, 2026 states that Henry Schein reported Q2 2026 adjusted EPS of $1.27, topping the consensus estimate of $1.22 by $0.05 per share. The same article notes that quarterly revenue reached $3.5 billion, modestly above expectations of $3.4 billion, which implies year-over-year revenue growth that keeps the company’s top line on an upward trajectory. The combination of a revenue beat and better-than-expected EPS suggests that Henry Schein delivered both volume growth and ongoing cost discipline in the second quarter.
The earnings overview further points out that analysts expect Henry Schein’s EPS for the fiscal year ending December 2026 to rise 7.7% to $5.35 on a diluted basis, aligning closely with management’s midpoint guidance of $5.34. This alignment between internal guidance and external expectations reduces forecast risk and gives investors a clearer view of the company’s earnings path over the next year.
Looking at valuation, a consensus snapshot as of August 20, 2026 shows Henry Schein’s last closing share price at $88.46 on the US market. The same consensus page lists the average analyst target price at $98.19, implying potential upside of 10.99% from the latest close if the stock were to reach the mean target. The overview also cites another measure of market expectations where the mean price target of $97.06 stands above the current price level, indicating that, on average, analysts still see room for share price appreciation.
Analyst views and guidance alignment
Recent analyst commentary compiled on August 20, 2026 indicates that the market has reacted positively to Henry Schein’s consistent record of outperforming earnings expectations. The compiled data underline that the company has beaten consensus EPS estimates in each of the last four quarters, reinforcing its reputation for reliable execution. One detailed report notes that a large investment bank maintained a positive rating on the stock with a price target of $102, which implies a premium of 14.2% to current trading levels cited in that analysis.
When set alongside the average target price of $98.19 reported on August 21, 2026, the $102 objective appears on the more optimistic end of the spectrum but still within a range supported by the company’s raised guidance. The gap between the current share price of $88.46 and these targets suggests that investors are waiting to see whether Henry Schein can sustain mid- to high-single-digit adjusted EBITDA growth and deliver on its raised 2026 EPS outlook.
An additional consensus page updated on August 21, 2026 lists Henry Schein’s last close at $88.49, down 0.90% for the day. The same broker research overview also shows that the stock has declined 1.83% over the previous five trading sessions but remains up 17.07% since the start of 2026. For investors, this means the shares have already delivered double-digit gains year to date, even though there has been some short-term consolidation.
Guidance, margins, and growth drivers
The August 21, 2026 outlook summary emphasizes that Henry Schein’s upgraded sales guidance is underpinned by both volume growth and ongoing margin momentum. The guidance breakdown makes clear that management expects internal local-currency growth in the second half of 2026 to run between 3.5% and 4.5%, a slight step up versus 3.6% growth in the first half despite tougher prior-year comparables. This indicates that the company is counting on continued demand from its dental and medical customers, as well as incremental contributions from its technology and value-added services.
The same update describes adjusted EBITDA growth in the mid- to high-single digits as a key objective for 2026. When paired with the EPS guidance range of $5.29 to $5.39, this suggests that Henry Schein aims to convert revenue growth into earnings at a stable or improving rate. Compared with the current analyst consensus EPS of $5.35 for the year ending December 2026, the midpoint of $5.34 shows only a narrow difference, giving investors a relatively tight band of expectations.
From a strategic perspective, the improved guidance can be seen in the context of Henry Schein’s long-term push to enhance its mix of higher-margin products and services. While the recent articles do not break out segment-level figures, the repeated reference to margin momentum in the August 21, 2026 guidance note underscores that cost efficiencies and mix shift remain central to the company’s growth story. If management can sustain mid- to high-single-digit adjusted EBITDA growth while keeping sales growth in the mid-single digits, the resulting operating leverage could support continued EPS expansion beyond 2026.
Product and service offering highlights
Henry Schein’s core business spans distribution of dental and medical supplies along with practice management software and services, which together give it a broad footprint across healthcare providers. The company’s value proposition rests on combining logistics capabilities with a wide product catalog, enabling dental and medical practices to source consumables, equipment, and digital solutions from a single partner. This integrated approach can help customers streamline procurement and focus on patient care, while providing Henry Schein with opportunities to deepen relationships and cross-sell services over time.
Beyond traditional supplies, Henry Schein has invested in digital platforms that support practice management, appointment scheduling, and clinical workflows. These solutions are designed to help practices increase efficiency, manage patient data securely, and enhance financial performance by tracking key metrics. By positioning these offerings alongside its distribution network, the company can benefit from a recurring revenue model where software and services complement periodic equipment purchases and consumables orders.
Henry Schein stock and recent trading levels
Henry Schein stock trades on the US market under the ticker HSIC. The consensus snapshot updated on August 20, 2026 records a last closing price of $88.46, while a broker research summary as of August 21, 2026 shows a slightly different last close of $88.49, reflecting minor variation between data providers. Using the $88.49 figure together with the average analyst target price of $98.19, the implied upside of 10.99% provides a numerical benchmark for how the market views the stock’s risk-reward profile over the medium term.
The same broker overview notes that Henry Schein shares were down 0.90% on the most recent trading day and had slipped 1.83% over the preceding five-day period, yet they remained up 17.07% year to date in 2026. For investors considering entry points, this mix of short-term pullback and solid year-to-date performance suggests that the stock has already captured part of the improvement in fundamentals but still trades below the consensus target range.
Read more
Dental supplies as a representative product line
A representative example of Henry Schein’s product offering is its broad range of dental consumables, which include items such as restorative materials, infection control products, and preventive care supplies. These consumables are essential for everyday dental procedures, and demand tends to track overall patient volumes and the frequency of routine check-ups and treatments. By supplying such products at scale, Henry Schein supports both small independent practices and larger group clinics, helping them manage costs and maintain consistent quality standards in patient care.
The company’s catalog also features equipment for dental practices, including chairs, imaging systems, and handpieces, which often involve longer sales cycles and larger ticket sizes. Bundling equipment with service contracts and software solutions gives Henry Schein the opportunity to build long-term relationships and generate recurring revenue from maintenance and upgrades. This equipment and consumables mix, combined with digital tools, forms a comprehensive ecosystem that can drive stickiness among customers and support the company’s internal growth targets.
Share price context for investors
As of the most recent trading session reflected in the August 21, 2026 broker research snapshot, Henry Schein stock closed at $88.49 in the US market. With an average analyst target price of $98.19 and some individual targets reaching $102, the shares are trading below the levels that many forecasts anticipate over the coming months. The year-to-date gain of 17.07% reported in the same data set shows that the stock has been responsive to improving fundamentals, including the Q2 2026 earnings beat and the raised 2026 sales and EPS outlook.
For investors evaluating Henry Schein, the key numbers from recent updates are the Q2 2026 adjusted EPS of $1.27 versus a $1.22 consensus, revenue of $3.5 billion versus expectations of $3.4 billion, and the upgraded full-year 2026 adjusted EPS guidance range of $5.29 to $5.39 paired with 4.5% to 5.5% projected total sales growth. Together with the current share price of $88.49 and the consensus target of $98.19, these figures frame a narrative of steady, moderately growing earnings supported by margin momentum and a diversified healthcare supply and services platform.
Fact box
Company: Henry Schein Inc.
ISIN: US42548G1040
Ticker: HSIC
Exchange: Nasdaq
Price (as of August 20, 2026, 3:59 p.m. ET): $88.49 USD
Sector / Industry: Health care / Health care distribution and services
Index membership: S&P 500
